# TRESR (NCT04497116)

> Study of RP-3500, Camonsertib, in Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04497116
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Repare Therapeutics
- Conditions: Advanced Solid Tumor
- Interventions: RP-3500 (camonsertib); Talazoparib; Gemcitabine Injection
- Enrollment: 276
- Primary outcome: Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above
- Primary outcome: Frequency of Dose Limiting Toxicity (DLT)

## Indexed commentary on TRESR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tresr-nct04497116